Enzyme replacement and enhancement therapies: Lessons from lysosomal disorders

被引：210

作者：

Desnick, RJ ^{[1
]}

Schuchman, EH ^{[1
]}

机构：

[1] NYU, Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA

来源：

NATURE REVIEWS GENETICS | 2002年 / 3卷 / 12期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nrg963

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The past decade has witnessed remarkable advances in our ability to treat inherited metabolic disorders, especially the lysosomal storage diseases, a group of more than 40 disorders, each of which is caused by the deficiency of a lysosomal enzyme or protein. During the past few years, both enzyme replacement and enhancement therapies have been developed to treat these disorders. This review discusses the successes and shortcomings of these therapeutic strategies, and the contributions that they have made to treating lysosomal storage diseases.

引用

页码：954 / 966

页数：13

共 114 条

[11] Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease
Bijvoet, AGA
van de Kamp, EHM
Kroos, MA
Ding, JH
Yang, BZ
Visser, P
Bakker, CE
Verbeet, MP
Oostra, BA
Reuser, AJJ
van der Ploeg, AT
[J]. HUMAN MOLECULAR GENETICS, 1998, 7 (01) : 53 - 62
[12] Bonten EJ, 2002, AM J HUM GENET, V71, P420
[13] REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - USE OF PURIFIED GLUCOCEREBROSIDASE IN GAUCHERS-DISEASE
BRADY, RO
PENTCHEV, PG
GAL, AE
HIBBERT, SR
DEKABAN, AS
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (19) : 989 - 993
[14] REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - USE OF PURIFIED CERAMIDETRIHEXOSIDASE IN FABRYS-DISEASE
BRADY, RO
TALLMAN, JF
JOHNSON, WG
GAL, AE
LEAHY, WR
QUIRK, JM
DEKABAN, AS
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (01) : 9 - 14
[15] Brady RO, 1991, TREATMENT GENETIC DI, P153
[16] BRADY RO, 1980, ENZYME THERAPY GENET, V2, P361
[17] Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models
Brooks, DA
[J]. MOLECULAR GENETICS AND METABOLISM, 1999, 68 (02) : 268 - 275
[18] Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO
[19] 2
[20] Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z:: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency
Burrows, JAJ
Willis, LK
Perlmutter, DH
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) : 1796 - 1801

← 1 2 3 4 5 6 7 8 9 10 →